Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 6/20 | 0.33 |
| ▸ | PDE4A | P27815 | 4/20 | 0.33 |
| ▸ | PDE4C | Q08493 | 4/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 4/20 | 0.33 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.31 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.30 |
| ▸ | P2RX3 | P56373 | 4/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5880768 | 0.99 | PDE4B (0.33) | PDE4BPDE4APDE4CPDE4DCSNK2A1 | |
| SCHEMBL3987522 | 0.89 | LMNA (0.38) | — | |
| SCHEMBL3989150 | 0.87 | SLC5A2 (0.35) | — | |
| SCHEMBL3988565 | 0.86 | P2RX3 (0.36) | P2RX3 | |
| SCHEMBL3988310 | 0.86 | PDE4B (0.34) | PDE4B | |
| SCHEMBL5880939 | 0.86 | ALDH1A1 (0.35) | — | |
| SCHEMBL5880753 | 0.85 | MEN1 (0.33) | PDE4BPDE4DP2RX3 | |
| SCHEMBL5880796 | 0.85 | HTR2A (0.39) | P2RX3 | |
| SCHEMBL3988490 | 0.85 | — | — | |
| SCHEMBL3985263 | 0.84 | PTGS1 (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7115658-B2 | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase | AGOURON PHARMACEUTICALS, INC. (US) | 2006-10-03 | — | — | US | disclosed |
| US-20040023958-A1 | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same | AGOURON PHARMACEUTICALS, INC. | 2004-02-05 | — | — | US | disclosed |
| WO-2003095441-A1 | INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME | PFIZER INC. (US) | 2003-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040023958-A1 | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same | POLRMT, RNGTT, RNASE1 | PDE4B 2179/4885PDE4A 1573/4885PDE4C 1618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.